In addition, whereas BBB-impermeant ACE inhibitors have little effect on Alzheimer’s disease symptoms, BBB-permeant inhibitors such as perindopril significantly delay the symptomatic progression in Alzheimer’s disease patients [43]. Here, ACE is linked to early-onset autosomal dominant Alzheimer disease.